Adherence to treatment with artemether-lumefantrine or amodiaquine-artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial

Kristin Banek, Emily L Webb, Samuel Juana Smith, Daniel Chandramohan, Sarah G Staedke, Kristin Banek, Emily L Webb, Samuel Juana Smith, Daniel Chandramohan, Sarah G Staedke

Abstract

Background: Prompt, effective treatment of confirmed malaria cases with artemisinin-based combination therapy (ACT) is a cornerstone of malaria control. Maximizing adherence to ACT medicines is key to ensuring treatment effectiveness.

Methods: This open-label, randomized trial evaluated caregiver adherence to co-formulated artemether-lumefantrine (AL) and fixed-dose amodiaquine-artesunate (AQAS) in Sierra Leone. Children aged 6-59 months diagnosed with malaria were recruited from two public clinics, randomized to receive AL or AQAS, and visited at home the day after completing treatment. Analyses were stratified by site, due to differences in participant characteristics and outcomes.

Results: Of the 784 randomized children, 680 (85.6%) were included in the final per-protocol analysis (340 AL, 340 AQAS). Definite adherence (self-reported adherence plus empty package) was higher for AL than AQAS at both sites (Site 1: 79.4% AL vs 63.4% AQAS, odds ratio [OR] 2.16, compared to probable adherence plus probable or definite non-adherence, 95% confidence interval [CI] 1.34-3.49; p = 0.001; Site 2: 52.1% AL vs 37.5% AQAS, OR 1.53, 95% CI 1.00-2.33, p = 0.049). However, self-reported adherence (ignoring drug package inspection) was higher for both regimens at both sites and there was no strong evidence of variation by treatment (Site 1: 96.6% AL vs 95.9% AQAS, OR 1.19, 95% CI 0.39-3.63, p = 0.753; Site 2: 91.5% AL vs 96.4% AQAS, OR 0.40, 95% CI 0.15-1.07, p = 0.067). In Site 2, correct treatment (correct dose + timing + duration) was lower for AL than AQAS (75.8% vs 88.1%, OR 0.42, 95% CI 0.23-0.76, p = 0.004). In both sites, more caregivers in the AQAS arm reported adverse events (Site 1: 3.4% AL vs 15.7% AQAS, p < 0.001; Site 2: 15.2% AL vs 24.4% AQAS, p = 0.039).

Conclusions: Self-reported adherence was high for both AL and AQAS, but varied by site. These results suggest that each regimen has potential disadvantages that might affect adherence; AL was less likely to be taken correctly at one site, but was better tolerated than AQAS at both sites. Measuring adherence to anti-malarials remains challenging, but important. Future research should focus on comparative studies of new drug regimens, and improving the methodology of measuring adherence.

Trial registration: Clinicaltrials.gov, NCT01967472. Retrospectively registered 18 October 2013, https://ichgcp.net/clinical-trials-registry/NCT01967472.

Keywords: Adherence; Amodiaquine; Artemether–lumefantrine; Artemisinin-based combination therapy (ACT); Artesunate; Co-formulated; Compliance; Fixed-dose combination; Malaria.

Figures

Fig. 1
Fig. 1
Map of the study area. Blue dots—study sites
Fig. 2
Fig. 2
Study profile. RDT, rapid diagnostic test; AQAS, fixed-dose combination amodiaquine–artesunate; AL, artemether–lumefantrine; SAE, serious adverse event

References

    1. WHO . T3: test, treat, track initiative. Geneva: World Health Organization; 2012.
    1. WHO . Guidelines for the treatment of malaria. 3. Geneva: World Health Organization; 2015.
    1. Banek K, Lalani M, Staedke SG, Chandramohan D. Adherence to artemisinin-based combination therapy for the treatment of malaria: a systematic review of the evidence. Malar J. 2014;13:7. doi: 10.1186/1475-2875-13-7.
    1. malERA Consultative Group on Health Systems and Operational Research A research agenda for malaria eradication: health systems and operational research. PLoS Med. 2011;8:e1000397. doi: 10.1371/journal.pmed.1000397.
    1. Orton LC, Barnish G. Unit-dose packaged drugs for treating malaria. Cochrane Database Syst Rev. 2005;2:CD004614.
    1. Yeboah-Antwi K, Gyapong J, Asare I, Barnish G, Evans D, Adjei S. Impact of prepackaging antimalarial drugs on cost to patients and compliance with treatment. Bull World Health Organ. 2001;79:394–399.
    1. Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ. 2004;82:935–939.
    1. WHO . The use of antimalarial drugs. Geneva: World Health Organization; 2001.
    1. Kauss T, Fawaz F, Guyot M, Lagueny A-M, Dos Santos I, Bonini F, et al. Fixed artesunate–amodiaquine combined pre-formulation study for the treatment of malaria. Int J Pharm. 2010;395:198–204. doi: 10.1016/j.ijpharm.2010.05.038.
    1. Abdulla S, Amuri B, Kabanywanyi AM, Ubben D, Reynolds C, Pascoe S, et al. Early clinical development of artemether–lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. Malar J. 2010;9:253. doi: 10.1186/1475-2875-9-253.
    1. Ansah E, Gyapong J, Agyepong I, Evans D. Improving adherence to malaria treatment for children: the use of pre-packed chloroquine tablets vs chloroquine syrup. Trop Med Int Health. 2001;6:496–504. doi: 10.1046/j.1365-3156.2001.00740.x.
    1. Teklehaimanot A, Teklehaimanot HD. Alternative form of artemether–lumefantrine for infants. Lancet. 2008;372:1786–1787. doi: 10.1016/S0140-6736(08)61493-2.
    1. Kolaczinski JH, Ojok N, Opwonya J, Meek S, Collins A. Adherence of community caretakers of children to pre-packaged antimalarial medicines (HOMAPAK®) among internally displaced people in Gulu district. Uganda. Malar J. 2006;5:40. doi: 10.1186/1475-2875-5-40.
    1. Delamou A, Delvaux T, El Ayadi AM, Beavogui AH, Okumura J, Van Damme W, et al. Public health impact of the 2014–2015 Ebola outbreak in West Africa: seizing opportunities for the future. BMJ Global Health. 2017;2:e000202. doi: 10.1136/bmjgh-2016-000202.
    1. Walker PG, White MT, Griffin JT, Reynolds A, Ferguson NM, Ghani AC. Malaria morbidity and mortality in Ebola-affected countries caused by decreased health-care capacity, and the potential effect of mitigation strategies: a modelling analysis. Lancet Infect Dis. 2015;15:825–832. doi: 10.1016/S1473-3099(15)70124-6.
    1. Brolin Ribacke KJ, Saulnier DD, Eriksson A, von Schreeb J. Effects of the West Africa Ebola virus disease on health-care utilization—a systematic review. Front Public Health. 2016;4:222. doi: 10.3389/fpubh.2016.00222.
    1. Hamel MJ, Slutsker L. Ebola: the hidden toll. Lancet Infect Dis. 2015;15:756–757. doi: 10.1016/S1473-3099(15)70167-2.
    1. Moses F, Tamang D, Denisiuk O, Dumbuya U, Hann K, Zachariah R. Management of malaria in children with fever in rural Sierra Leone in relation to the 2014–2015 Ebola outbreak. Public Health Action. 2017;7:S22–S26. doi: 10.5588/pha.16.0085.
    1. Checchi F, Roddy P, Kamara S, Williams A, Morineau G, Wurie AR, et al. Evidence basis for antimalarial policy change in Sierra Leone: five in vivo efficacy studies of chloroquine, sulphadoxine-pyrimethamine and amodiaquine. Trop Med Int Health. 2005;10:146–153. doi: 10.1111/j.1365-3156.2004.01367.x.
    1. Gerstl S, Dunkley S, Mukhtar A, Baker S, Maikere J. Successful introduction of artesunate combination therapy is not enough to fight malaria: results from an adherence study in Sierra Leone. Trans R Soc Trop Med Hyg. 2010;104:328–335. doi: 10.1016/j.trstmh.2009.12.008.
    1. National Malaria Control Programme (NMCP) Guidelines for case management of malaria. Freetown: Government of Sierra Leone Ministry of Health and Sanitation; 2015.
    1. Bell DJ, Wootton D, Mukaka M, Montgomery J, Kayange N, Chimpeni P, et al. Measurement of adherence, drug concentrations and the effectiveness of artemether–lumefantrine, chlorproguanil–dapsone or sulphadoxine–pyrimethamine in the treatment of uncomplicated malaria in Malawi. Malar J. 2009;8:204. doi: 10.1186/1475-2875-8-204.
    1. Dunyo S, Sirugo G, Sesay S, Bisseye C, Njie F, Adiamoh M, et al. Randomized trial of safety and effectiveness of chlorproguanil–dapsone and lumefantrine–artemether for uncomplicated malaria in children in the Gambia. PLoS ONE. 2011;6:e17371. doi: 10.1371/journal.pone.0017371.
    1. Faucher JF, Aubouy A, Adeothy A, Cottrell G, Doritchamou J, Gourmel B, et al. Comparison of sulfadoxine-pyrimethamine, unsupervised artemether–lumefantrine, and unsupervised artesunate–amodiaquine fixed-dose formulation for uncomplicated Plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial. J Infect Dis. 2009;200:57–65. doi: 10.1086/599378.
    1. WHO . Guidelines for the treatment of malaria. 2. Geneva: World Health Organization; 2010.
    1. Sierra Leone Ministry of Health and Sanitation . Guidelines for case management of malaria in Sierra Leone. 3. Freetown: Sierra Leone Ministry of Health and Sanitation; 2010.
    1. Dawson AJ. Methodological reasons for not gaining prior informed consent are sometimes justified. BMJ. 2004;329:87. doi: 10.1136/bmj.38112.692211.F7.
    1. Ratsimbasoa A, Ravony H, Vonimpaisomihanta J-A, Raherinjafy R, Jahevitra M, Rapelanoro R, et al. Compliance, safety, and effectiveness of fixed-dose artesunate–amodiaquine for presumptive treatment of non-severe malaria in the context of home management of malaria in Madagascar. Am J Trop Med Hyg. 2012;86:203–210. doi: 10.4269/ajtmh.2012.11-0047.
    1. Bruxvoort K, Goodman C, Kachur SP, Schellenberg D. How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs. PLoS ONE. 2014;9:e84555. doi: 10.1371/journal.pone.0084555.
    1. Yeung S, White NJ. How do patients use antimalarial drugs? A review of the evidence. Trop Med Int Health. 2005;10:121–138. doi: 10.1111/j.1365-3156.2004.01364.x.
    1. Vyas S, Kumaranayake L. Constructing socio-economic status indices: how to use principal components analysis. Health Policy Plan. 2006;21:459–468. doi: 10.1093/heapol/czl029.
    1. WHO . World Malaria Report 2016. Geneva: World Health Organization; 2017.
    1. Rahman MM, Dondorp AM, Day NPJ, Lindegardh N, Imwong M, Faiz MA, et al. Adherence and efficacy of supervised versus non-supervised treatment with artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial. Trans R Soc Trop Med Hyg. 2008;102:861–867. doi: 10.1016/j.trstmh.2008.05.022.
    1. Mubi M, Janson A, Warsame M, Mårtensson A, Källander K, Petzold MG, et al. Malaria rapid testing by community health workers is effective and safe for targeting malaria treatment: randomised cross-over trial in Tanzania. PLoS ONE. 2011;6:e19753. doi: 10.1371/journal.pone.0019753.
    1. Bruxvoort K, Festo C, Kalolella A, Cairns M, Lyaruu P, Kenani M, et al. Cluster randomized trial of text message reminders to retail staff in tanzanian drug shops dispensing artemether–lumefantrine: effect on dispenser knowledge and patient adherence. Am J Trop Med Hyg. 2014;91:844–853. doi: 10.4269/ajtmh.14-0126.
    1. Raifman JR, Lanthorn HE, Rokicki S, Fink G. The impact of text message reminders on adherence to antimalarial treatment in northern Ghana: a randomized trial. PLoS ONE. 2014;9:e109032. doi: 10.1371/journal.pone.0109032.
    1. Talisuna A, Zurovac D, Githinji S, Oburu A, Malinga J, Nyandigisi A. Efficacy of mobile phone short message service (SMS) reminders on malaria treatment adherence and day 3 post-treatment reviews (SMS-RES-MAL) in Kenya: a study protocol. J Clin Trials. 2015;5:2167.
    1. Liu JX, Modrek S. Evaluation of SMS reminder messages for altering treatment adherence and health seeking perceptions among malaria care-seekers in Nigeria. Health Policy Plan. 2016;31:1374–1383. doi: 10.1093/heapol/czw076.
    1. Asante KP, Owusu R, Dosoo D, Awini E, Adjei G, Etego SA, et al. Adherence to artesunate-amodiaquine therapy for uncomplicated malaria in rural Ghana: a randomised trial of supervised versus unsupervised drug administration. J Trop Med. 2009;2009:529583. doi: 10.1155/2009/529583.
    1. Beer N, Ali AS, Rotllant G, Abass AK, Omari RS, Al-mafazy A-wH, et al. Adherence to artesunate–amodiaquine combination therapy for uncomplicated malaria in children in Zanzibar, Tanzania. Trop Med Int Health. 2009;14:766–774. doi: 10.1111/j.1365-3156.2009.02289.x.
    1. Gerstl S, Namagana A, Palacios L, Mweshi F, Aprile S, Lima A. High adherence to malaria treatment: promising results of an adherence study in South Kivu, Democratic Republic of the Congo. Malar J. 2015;14:414. doi: 10.1186/s12936-015-0933-7.
    1. Siddiqui MR, Willis A, Bil K, Singh J, Sompwe EM, Ariti C. Adherence to artemisinin combination therapy for the treatment of uncomplicated malaria in the Democratic Republic of the Congo. F1000Research. 2015;4:51.
    1. Novartis . Coartem monograph. vol. 4. Basel: Novartis Pharma AG; 2005.
    1. Gore-Langton GR, Alenwi N, Mungai J, Erupe NI, Eves K, Kimwana FN, et al. Patient adherence to prescribed artemisinin-based combination therapy in Garissa County, Kenya, after three years of health care in a conflict setting. Malar J. 2015;14:125. doi: 10.1186/s12936-015-0645-z.
    1. Lin JT, Juliano JJ, Wongsrichanalai C. Drug-resistant malaria: the era of ACT. Curr Infect Dis Rep. 2010;12:165–173. doi: 10.1007/s11908-010-0099-y.
    1. Bompart F, Kiechel JR, Sebbag R, Pecoul B. Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience. Malar J. 2011;10:143. doi: 10.1186/1475-2875-10-143.
    1. Drugs for Neglected Diseases Initiative (DNDi). Press Pack for ASAQ. 2007.
    1. Lacaze C, Kauss T, Kiechel JR, Caminiti A, Fawaz F, Terrassin L, et al. The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public–private partnership. Malar J. 2011;10:142. doi: 10.1186/1475-2875-10-142.
    1. Cairns M, Cisse B, Sokhna C, Cames C, Simondon K, Ba E, et al. Amodiaquine dosage and tolerability for intermittent preventive treatment to prevent malaria in children. Antimicrob Agents Chemother. 2010;54:1265–1274. doi: 10.1128/AAC.01161-09.
    1. Lemma H, Lofgren C, San Sebastian M. Adherence to a six-dose regimen of artemether–lumefantrine among uncomplicated Plasmodium falciparum patients in the Tigray Region, Ethiopia. Malar J. 2011;10:349. doi: 10.1186/1475-2875-10-349.
    1. Abdulla S, Sagara I. Dispersible formulation of artemether–lumefantrine: specifically developed for infants and young children. Malar J. 2009;8(Suppl 1):S7. doi: 10.1186/1475-2875-8-S1-S7.
    1. Tadesse AN, Eshetu EM. Artemether–lumefantrine: pediatric formulations for the treatment of uncomplicated Plasmodium falciparum. J Sci Innov Res. 2014;3:102–111.
    1. Bassat Q. The unmet needs of paediatric therapeutics in poor countries. 3. Oxford: Oxford University Press; 2015.
    1. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21:1074–1090. doi: 10.1016/S0149-2918(99)80026-5.
    1. Turner BJ, Hecht FM. Improving on a coin toss to predict patient adherence to medications. Ann Intern Med. 2001;134:1004–1006. doi: 10.7326/0003-4819-134-10-200105150-00015.
    1. elMasry N, Kipkeu C. Innovation in malaria drug packaging: Coartem® and Coartem® dispersible. International Pharmaceutical Industry (IPI) 2009, Winter 2009/10 newsletter.
    1. Cohen J, Saran I, Yavuz E. The impact of packaging and messaging on adherence to malaria treatment: evidence from a randomized controlled trial in Uganda. 2014. . Accessed 31 May 2018.
    1. Fuangchan A, Dhippayom T, Kongkaew C. Intervention to promote patients’ adherence to antimalarial medication: a systematic review. Am J Trop Med Hyg. 2014;90:11–19. doi: 10.4269/ajtmh.12-0598.
    1. Bruxvoort K, Festo C, Cairns M, Kalolella A, Mayaya F, Kachur SP, et al. Measuring patient adherence to malaria treatment: a comparison of results from self-report and a customised electronic monitoring device. PLoS ONE. 2015;10:e0134275. doi: 10.1371/journal.pone.0134275.
    1. Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J, et al. Adherence to a six-dose regimen of artemether–lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Am J Trop Med Hyg. 2004;71:525–530.
    1. Talisuna AO, Oburu A, Githinji S, Malinga J, Amboko B, Bejon P, et al. Efficacy of text-message reminders on paediatric malaria treatment adherence and their post-treatment return to health facilities in Kenya: a randomized controlled trial. Malar J. 2017;16:46. doi: 10.1186/s12936-017-1702-6.
    1. Mace KE, Mwandama D, Jafali J, Luka M, Filler SJ, Sande J, et al. Adherence to treatment with artemether–lumefantrine for uncomplicated malaria in rural Malawi. Clin Infect Dis. 2011;53:772–779. doi: 10.1093/cid/cir498.
    1. Bruxvoort K, Kalolella A, Cairns M, Festo C, Kenani M, Lyaruu P, et al. Are Tanzanian patients attending public facilities or private retailers more likely to adhere to artemisinin-based combination therapy? Malar J. 2015;14:87. doi: 10.1186/s12936-015-0602-x.
    1. Saran I, Yavuz E, Kasozi H, Cohen J. Can rapid diagnostic testing for malaria increase adherence to artemether–lumefantrine?: a randomized controlled trial in Uganda. Am J Trop Med Hyg. 2016;94:857–867. doi: 10.4269/ajtmh.15-0420.
    1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497. doi: 10.1056/NEJMra050100.
    1. Achan J, Tibenderana JK, Kyabayinze D, Wabwire Mangen F, Kamya MR, Dorsey G, et al. Effectiveness of quinine versus artemether–lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ. 2009;339:b2763. doi: 10.1136/bmj.b2763.
    1. Cohen JL, Yavuz E, Morris A, Arkedis J, Sabot O. Do patients adhere to over-the-counter artemisinin combination therapy for malaria? evidence from an intervention study in Uganda. Malar J. 2012;11:83. doi: 10.1186/1475-2875-11-83.
    1. Anyanwu P, Fulton J, Paget T, Evans E. Socioeconomic determinants of antimalarial drug use behaviours: a systematic review. J Comm Public Health Nursing. 2016;2:123. doi: 10.4172/2471-9846.1000123.
    1. Leonard K, Masatu MC. Outpatient process quality evaluation and the Hawthorne effect. Soc Sci Med. 2006;63:2330–2340. doi: 10.1016/j.socscimed.2006.06.003.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren